ORXOY - Orexo AB (publ)

Other OTC - Other OTC Delayed Price. Currency in USD

0.9720

0.0000

(0.00%)

At close: 01:12PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	0.9720
Open	0.9720
Bid	0.0000 x 0
Ask	0.0000 x 0
Day's Range	0.9720 - 0.9720
52 Week Range	0.9720 - 2.8200
Volume	100
Avg. Volume	43

Market Cap	33.405M
Beta (5Y Monthly)	0.60
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ORXOY

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Press Releases

PR Newswire
Orexo Interim Report Q1 2023
Focusing operations on Orexo´s strengths
PR Newswire
Report from Orexo AB's annual general meeting
Election of the board of directors and auditor
PR Newswire
Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose, is delayed to late 2024 from previously first half of 2024, if approved by the US Food and Drug Administration (FDA) according to their ordinary timelines.
PR Newswire
Orexo publishes the Annual and Sustainability Report for 2022
Orexo's Annual and Sustainability Report for 2022 has been published and can be downloaded at, www.orexo.com, where it is also available in Swedish in accordance with the European Single Electronic Format (ESEF). A PDF version of the report is attached to this press release.
PR Newswire
Orexo postpones publication of the Annual Report
Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously announced date for publication was March 24, 2023. The change in date is due to prolonged audit of the financial reporting in the European Single Electronic Format, ESEF.
PR Newswire
Notice of Annual General Meeting of Orexo
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Tuesday 18 April 2023, at 16.00 pm in Orexo's facilities at Rapsgatan 7E in Uppsala, Sweden.
PR Newswire
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose. OX124, is based on Orexo´s drug delivery platform amorphOX® and contains a high-dose of naloxone.
PR Newswire
Orexo Interim Report Q4 2022, incl. Full Year Report
Important steps forward in a challenging environment
PR Newswire
Orexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companies
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory feasibility studies, applying the proprietary drug delivery platform amorphOX® to protein based pharmaceuticals and vaccines in collaboration with leading international biopharmaceutical and vaccine companies. The feasibility studies follow successful formulation of the Covid-19 spike protein in amorphOX®.
GlobeNewswire
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the presentations from its KCSA Mental Health Virtual Investor Conference held on December 15th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3FPSRgWThe company presentations will be
GlobeNewswire
Orexo to Webcast Live at VirtualInvestorConferences.com December 15th
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.comMORRISTOWN, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Orexo (STO:ORX) (OTCQX:ORXOY), which develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health, today announced that Nikolaj Sørensen, President and CEO, will present live at VirtualInves
GlobeNewswire
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Mental Health Virtual Investor Conference to be held on Thursday, December 15, 2022. Individual investors, institutional investors, advisors, and analysts are invited to atte
PR Newswire
Orexo Interim Report Q3 2022
Advancing the pipeline facilitating future growth
PR Newswire
Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the last participant has enrolled in the pivotal study of the digital therapeutic MODIA® as part of a clinician supervised medication-assisted treatment program for the treatment of opioid use disorder (OUD). The randomized, open-label, parallel-group study is evaluating whether the use of MODIA® in combination with sublingual buprenorphine/naloxone background therapy is superior to sublingual buprenorphine/naloxone alone to reduce illic
PR Newswire
Orexo appoints Edward Kim, M.D., as new Chief Medical Officer
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today welcomes Edward (Ed) Kim, M.D., as new Chief Medical Officer (CMO). Ed Kim will succeed Michael Sumner, M.D., who has held this role since 2013. He is located at Orexo´s US subsidiary in Morristown, New Jersey.
PR Newswire
Orexo´s Nomination Committee for the Annual General Meeting 2023
Prior to the Annual General Meeting (AGM) that will take place on April 18, 2023, a Nomination Committee has been appointed comprising the same members as ahead of the AGM hosted earlier this year:
PR Newswire
Orexo announces positive data from phase 1 clinical study for OX640 - a nasal epinephrine rescue medication for allergic reactions
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces positive results from the first explorative human clinical study (OX640-001) for its nasal epinephrine (adrenaline) rescue medication for allergic reactions, OX640. The study was a comparative bioavailability study performed in 40 healthy volunteers assessing four investigational formulations of OX640 compared to a marketed epinephrine auto-injector.
PR Newswire
Orexo's partner Trinity Health today announces the availability of vorvida® and deprexis® to patients
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with Orexo, is expanding patient access to digital therapeutics. Trinity Health will now offer Orexo's evidence-based digital therapies vorvida® and deprexis® to help patients manage depression and excessive drinking.
PR Newswire
First patent issued in Europe for Orexo's adrenaline product OX640
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the European Patent Office (EPO) has granted the first European patent specifically relating to OX640, Orexo's nasal adrenaline rescue medication based on the amorphOX® drug delivery platform.
PR Newswire
Orexo to participate in Pareto Securities´ 13th Annual Healthcare Conference
Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), which develops improved pharmaceuticals and evidence-based digital therapeutics primarily targeting the US market where its commercial organization is located, today announces the company will participate in Pareto Securities' 13th Annual Healthcare Conference, that takes place on September 7-8, 2022, at Sergel Hub, Sveavägen 10 A, Stockholm, Sweden.
PR Newswire
Orexo Interim Report Q2 2022
Good tailwind in the financial development
PR Newswire
Orexo's digital therapy deprexis® reimbursed under the US Veterans Affairs Federal Supply Schedule
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), announced today it has been granted a Veteran Affairs Federal Supply Schedule (VA FFS) contract for deprexis®, an evidence-based digital therapy for the treatment of symptoms of depression. As of late July 2022, deprexis® will be reimbursed by the federal government and made available to federal healthcare providers, including Veterans Affairs (VA), Indian Health Service (IHS) and Department of Defense (DOD). The contract will expire in 2032.
PR Newswire
Orexo's nasal adrenaline rescue medication OX640 enters clinical development
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has successfully initiated the first explorative human clinical study (OX640-001) for OX640, an adrenaline rescue medication with nasal delivery. The study aims to determine the relative bioavailability and absorption characteristics of investigational OX640 formulations versus an intramuscular adrenaline injection in healthy volunteers.
GlobeNewswire
Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing
NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3nbZJuOThe company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accepting 1x1 manag
GlobeNewswire
UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23rd. Individual investors, institutional investors, advisors, and analysts are invited to attend. The program begins at 9:30 AM EDT on Thursday,